Michelle Monje, MD, PhD

Her lab demonstrated that neuronal activity regulates healthy glial precursor cell proliferation, new oligodendrocyte generation and adaptive myelination (Gibson et al., 2014 Science) and that this plasticity of myelin contributes to healthy cognitive function (Geraghty et al, 2019 Neuron; Steadman et al., 2019 Neuron). She discovered that neuronal activity similarly promotes the proliferation of malignant glioma cells, driving glioma growth through both paracrine factors and through electrophysiologically functional neuron-to-glioma synapses (Venkatesh et al., 2015, Cell; Venkatesh et al., 2017 Nature; Venkatesh et al., 2019 Nature).

In addition to these studies of mature neurons in the glioma microenvironment, her research program also study the influences of neural precursor cells on malignant glioma (Qin et al., 2017, Cell). Microglial interactions with neurons and neural precursor cells and microglial-mediated disruption of neuroplasticity mechanisms underlying cognitive function following cancer therapies is another area of deep focus (Monje et al, 2002, Nature Medicine, Monje et al, 2003, Science, Monje et al, 2007, Annals of Neurology, Gibson et al., 2019 Cell; Geraghty et al, 2019 Neuron). Together with these basic studies, her research program executes preclinical studies of novel therapeutics for pediatric high-grade gliomas (Grasso et al, 2015, Nature Medicine; Nagaraja et al, 2017, Cancer Cell; Mount et al, 2018 Nature Medicine; Lin et al, 2019 Science Translational Medicine) and cancer therapy-related cognitive impairment (Gibson et al., 2019 Cell; Geraghty et al, 2019 Neuron) in order to translate new therapies to the clinic. She has led several of her discoveries to national, cooperative clinical trials for children with brain tumors.

Dr. Monje is recognized as an international leader in the pathophysiology of childhood gliomas, especially diffuse midline gliomas and diffuse intrinsic pontine glioma (DIPG). Her work has been recognized by numerous honors, including a Presidential Early Career Award for Science and Engineering (PECASE), an NIH Director’s Pioneer Award (DP1), the Sidney Carter Award in Child Neurology and the Jerome Posner Neuro-Oncology Investigator Award, from the American Academy of Neurology. She is on the editorial advisory board for multiple academic journals, including Cancer Cell, Neuron and Neuro-Oncology.

Dr. Monje received her M.D. and Ph.D. in Neuroscience from Stanford University and then completed her residency training in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School Partners program. She returned to Stanford for a clinical fellowship in pediatric neuro-oncology and a post-doctoral fellowship with Dr. Philip Beachy.

Awards and Recognitions

2023	Paul Marks Prize in Cancer Research, The Marks Foundation and MSKCC
2023	Richard Lounsbery Award, National Academy of Science
2023	Jonathan Kraft Prize for Excellence in Cancer Research, Massachusetts General Hospital
2021	The MacArthur Foundation Fellowship
2021	Appointment as a Howard Hughes Medical Institute Investigator
2021	Elected to the National Academy of Medicine
2020	F.E. Bennett Memorial Lectureship Award, American Neurological Association
2020	Stanford Medicine Endowed Faculty Scholar
2019	Sidney Carter Award in Child Neurology, American Academy of Neurology
2019	Presidential Early Career Award in Science and Engineering (PECASE)
2018	NIH Director’s Pioneer Award
2017	The Jerome Posner Neuro-Oncology Investigator Award, American Academy of Neurology
2017	The Innovative Researcher Award, DIPG Collaborative

Recent and Notable Publications